Request Trial
1 May 2011AsiaArchana Shanker

A revolution: biotech patents in India

In May 2011, Glenmark Pharmaceuticals entered into a licence agreement with Sanofi Aventis in one of the first-ever deals for a novel biologic molecule in India for the treatment of autoimmune diseases. Bharat Biotech, an Indian Biotech company, developed a diarrhoea vaccine to be supplied to the UN and other markets at $1 each, making it the cheapest vaccine available in the market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Chinese biotech strikes billion dollar deal in nextgen cancer race
20 January 2026   Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.
Asia
Novo Nordisk secures China win ahead of key patent expiration
6 January 2026   Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.
Asia
Novo Nordisk ramps up semaglutide defence as generics lurk
9 December 2025   The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

Chinese biotech strikes billion dollar deal in nextgen cancer race
From migraine drugs to COVID vaccine spats, US lawsuits pile up
How AI will be shaped by legal and regulatory developments in 2026
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
Novo Nordisk secures China win ahead of key patent expiration
Key EU and UK regulatory changes to watch for in 2026
Mental health in IP: ‘We have a clear picture of the problem’
From Edwards to Insulet: Three key medical device cases of 2025